Feature Article

Herpes zoster: improving protection in older people



1.    Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Canberra: Australian Government Department of Health; 2018. Available online at: (accessed February 2019).
2.    Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013; 26: 728-743.
3.    Cunningham AL, Levin MJ. Herpes zoster vac­cines. J Infect Dis 2018; 218 (Suppl_2): S127-S133.
4.    Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the under­standing of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 (Suppl 1): S2-S7.
5.    Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4: e004833.
6.    MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing trends of herpes zoster in Australia. PLoS One 2015; 10: e0125025.
7.    Marin M, Harpaz R, Zhang J, Wollan PC, Bialek SR, Yawn BP. Risk factors for herpes zoster among adults. Open Forum Infect Dis 2016; 3: ofw119.
8.    Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc 2017; 92: 1806-1821.
9.    Kennedy PGE, Gershon AA. Clinical features of varicella-zoster vrus infection. Viruses 2018; 10: 609; doi: 10.3390/v10110609.
10. National Centre for Immunisation Research and Surveillance (NCIRS). Zoster vaccine. Frequently asked questions: information for immunisation providers. Sydney: NCIRS; 2018. Available online at: (accessed February 2019).
11.    Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis 2014; 14: 402.
12.    Dwyer DE, Cunningham AL. 10: Herpes simplex and varicella-zoster virus infections. Med J Aust 2002; 177: 267-273.
13.    Rawlinson WD, Dwyer DE, Gibbons VL, Cunningham AL. Rapid diagnosis of varicella-zoster virus infection with a monoclonal antibody based direct immunofluorescence technique. J Virol Methods 1989; 23: 13-18.
14.    Johnson RW, Rice AS. Clinical practice. Posthe­r­petic neuralgia. N Engl J Med 2014; 371: 1526-1533.
15.    Dworkin R, Schmader K. Epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson CPN GA, ed. Herpes zoster and postherpetic neuralgia. New York: Elsevier Press; 2001. pp. 39-64.
16.    Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009; 27: 520-529.
17.    Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Anti­viral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014; (2): CD006866.
18.    Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157: 30-54.
19.    Zorzoli E, Pica F, Masetti G, Franco E, Volpi A, Gabutti G. Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. Aging Clin Exp Res 2018; 30: 693-702.
20.    Kovac M, Lal H, Cunningham AL, et al; ZOE-50/70 Study Group. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine 2018; 36: 1537-1541.
21.    Yang SY, Li HX, Yi XH, et al. Risk of stroke in patients with herpes zoster: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2017; 26: 301-307.
22.    Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis 2017; 17: 198.
23.    Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) guideline on the management of herpes zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol 2017; 31: 20-29.
24.    John AR, Canaday DH. Herpes zoster in the older adult. Infect Dis Clin North Am 2017; 31: 811-826.
25.    Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900.
26.    Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2013; (3): CD005582.
27.    Chen N, Yang M, He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2010; (12): CD005582.
28.    Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand 2011; 123: 295-309.
29.    Hadley GR, Gayle JA, Ripoll J, et al. Post-herpetic neuralgia: a review. Curr Pain Headache Rep 2016; 20: 17.
30.    Meng FY, Zhang LC, Liu Y, et al. Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. Minerva Anestesiol 2014; 80: 556-567.
31.    Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; (3): CD007076.
32.    Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; (1): CD011209.
33.    Dosenovic S, Jelicic Kadic A, Miljanovic M, et al. Interventions for neuropathic pain: an overview of sys­­tematic reviews. Anesth Analg 2017; 125: ­643-652.
34.    Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol 2016; 16: 12.
35.    Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
36.    Tseng HF, Harpaz R, Luo Y, et al. Declining effec­tiveness of herpes zoster vaccine in adults 60 years and older. J Infect Dis 2016; 213: 1872-1875.
37.    Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep 2016; 2016: bcr2015212688.
38.    Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine 2017; 35: 7231-7239.
39.    Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-49.
40.    National Centre for Immunisation Research and Surveillance (NCIRS). Herpes zoster factsheet. Zoster vaccine for Australian adults: information for immunisa­tion providers. Sydney: NCIRS; 2017. Available online at: (accessed February 2019).
41.    Australian Government Department of Health. Zostavax vaccine screening form for contraindication. January 2018 (updated July 2018). Canberra: Department of Health; 2018. Available online at: (accessed February 2019). 
42.    Shiraki K, Toyama N, Daikoku T, Yajima M. Herpes zoster and recurrent herpes zoster. Open Forum Infect Dis 2017; 4: ofx007.
43.    Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Inf Dis 2008; 197: 825-835.
44.    Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27: 882-887.
45.    Yang TU, Cheong HJ, Song JY, Noh JY, Kim WJ. Survey on public awareness, attitudes, and barriers for herpes zoster vaccination in South Korea. Hum Vaccin Immunother 2015; 11: 719-726.
46.    Opstelten W, van Essen GA, Hak E. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine 2009; 27: 192-196.
47.    Yang TU, Cheong HJ, Choi WS, Song JY, Noh JY, Kim WJ. Physician attitudes toward the herpes zoster vaccination in South Korea. Infect Chemother 2014; 46: 194-198.
48.    Joon Lee T, Hayes S, Cummings DM, et al. Herpes zoster knowledge, prevalence, and vaccination rate by race. J Am Board Fam Med 2013; 26: 45-51.
49.    Teeter BS, Garza KB, Stevenson TL, Williamson MA, Zeek ML, Westrick SC. Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies. Vaccine 2014; 32: 5749-5754.
50.    Lu PJ, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med 2011; 40: e1-e6.
51.    Hechter RC, Tartof SY, Jacobsen SJ, Smith N, Tseng HF. Trends and disparity in zoster vaccine uptake in a managed care population. Vaccine 2013; 31: 4564-4568. 
52.    Javed S, Javed F, Mays RM, Tyring SK. Herpes zoster vaccine awareness among people ≥50 years of age and its implications on immunization. Dermatol Online J 2012; 18: 2. 
53.    Damm O, Witte J, Greiner W. A systematic review of herpes zoster vaccine acceptance. Value Health 2015; 18: A592.
54.    Roh NK, Park YM, Kang H, et al. Awareness, knowledge, and vaccine acceptability of herpes zoster in Korea: a multicenter survey of 607 patients. Ann Dermatol 2015; 27: 531-538.
55.    Chi RC, Reiber GE, Neuzil KM. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. J Am Geriatr Soc 2006; 54: 217-223.
56.    Pearson WS, Dube SR, Ford ES, Mokdad AH. Influenza and pneumococcal vaccination rates among smokers: data from the 2006 Behavioral Risk Factor Surveillance System. Prev Med 2009; 48: 180-183.
57.    Lu PJ, Singleton JA, Rangel MC, Wortley PM, Bridges CB. Influenza vaccination trends among adults 65 years or older in the United States, 1989-2002. Arch Intern Med 2005; 165: 1849-1856.
58. Ndiaye S, Hopkins D, Shefer A, et al. Interven­tions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among high-risk adults: a systematic review. Am J Prev Med 2005; 28 (5 Suppl): 248-279. 
59. Kamal KM, Madhavan SS, Amonkar MM. Determi­nants of adult influenza and pneumonia immunization rates. J Am Pharm Assoc 2003; 43: 403-411. 
60.    MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin 2010; 6: 894-902.
61.    Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant admin­istration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011; 29: 3628-3632.
62.    Lal H, Cunningham AL, Godeaux O, et al; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087-2096.
63.    Cunningham AL, Lal H, Kovac M, et al; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375: 1019-1032.
64.    Tricco AC, Zarin W, Cardoso R, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ 2018; 363: k4029.
COMPETING INTERESTS: Associate Professor Litt has received funds for sitting on advisory boards for Seqirus and GlaxoSmithKline and speaker’s fees from Seqirus when providing educational updates on zoster vaccination for a range of healthcare providers. Professor Cunningham has received other funding for his institution from Merck, BioCSL/Seqirus and GlaxoSmithKline, outside the submitted work.


Associate Professor Litt is a Public Health Physician and Associate Professor in the Discipline of General Practice, Flinders University, Adelaide, SA. Professor Cunningham is Executive Director of the Westmead Institute for Medical Research and Professor of Research Medicine at The University of Sydney, Sydney, NSW.